In response to "Selective serotonin reuptake inhibitors--a new modality for the treatment of lymphoma/leukaemia?" by C. Schuster, et al. [Biochem. Pharmacol. 74 (9) 2007 1424-1435].
Gordon
John
J
Barnes
Nicholas
N
Meredith
Elisabeth
E
Drayson
Mark
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D045744:Cell Line, Tumor; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D005473:Fluoxetine; D019253:Proto-Oncogene Proteins c-bcl-2; D017367:Selective Serotonin Reuptake Inhibitors